1 Sezer A, Kilickap S, Gümüs M, Bondarenko I, Özgüroglu M, Gogishvili M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397:592-604.
2 Gogishvili M, Melkadze T, Makharadze T, Giorgadze D, Dvorkin M, Penkov K, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial. Nat Med 2022;28(11):2374-80.
3 Kilickap S, Özgüroglu M, Sezer A, Gumus M, Bondarenko I, Gogishvili M, et al. EMPOWER-Lung 1: Cemiplimab (CEMI) monotherapy as first-line (1L) treatment of patients (pts) with brain metastases from advanced non-small cell lung cancer (aNSCLC) with programmed cell death-ligand 1 (PD-L1) _50%: 3-year update. ELCC 2023; abstract 10MO.
4 Mansfield AS, Herbst RS, de Castro G, Hui R, Peled N, Kim D-W, et al. Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. JTO Clin Res Rep 2021;2(8):100205.
5 Makharadze T, Gogishvili M, Melkadze T, Baramidze A, Giorgadze D, Penkov KD, et al. Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: longer follow-up results from the Phase 3 EMPOWER-Lung 3 trial. ELCC 2023; abstract 5O.
6 Neal JW, Santoro A, Viteri S, Ponce Aix S, Fang B, Lim FL, et al. Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor (ICI): Results from Cohorts 7 and 20 of the COSMIC-021 study. J Clin Oncol 2022;40: no. 16_suppl; abstract 9005.
7 Neal J, Pavlakis N, Kim S, Lim S, Mountzios G, Fountzilas E, et al. CONTACT-01: Efficacy and safety from a Ph 3 study of atezolizumab (atezo) + cabozantinib (cabo) vs docetaxel (doc) monotherapy in patients (pts) with metastatic NSCLC (mNSCLC) previously treated with checkpoint inhibitors and chemotherapy. ELCC 2023; abstract 6O.
8 De Langen AJ, Johnson ML, Mazieres J, Dingemans AMC, Mountzios G, Pless M, et al. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial. Lancet 2023;401(10378):733-46.
9 Waterhouse DM, Rothschild SI, Dooms C, Mennecier B, Bozorgmehr F, Majem Tarruella M, et al. Patient-reported outcomes from the CodeBreaK 200 phase 3 trial comparing sotorasib versus docetaxel in KRAS G12C-mutated NSCLC. ELCC 2023; abstract 4O.
10 Maimon N, Stevenson JP, Petty W, Ferreira CM, Morbeck I, Zer A, et al. Sotorasib in KRAS G12C-mutated advanced non-small cell lung cancer (aNSCLC): overall survival (OS) data from the global expanded access program (EAP study-436). ELCC 2023; abstract 7MO.
11 Jänne PA, Riely GJ, Gadgeel SM, Heist RS, Ou SHI, Pacheco JM, et al. Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation. N Engl J Med. 2022;387:120-131.
12 Jänne PA, Spira A, Riely GJ, Gadgeel S, Heist R, Ou S, et al. Adagrasib (MRTX849) in Patients With Advanced/Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer (NSCLC): Preliminary Analysis of Mutation Allele Frequency. ELCC 2023; abstract 8MO.
13 Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386:1973-1985. N Engl J Med. 2022;386:1973-85.
14 Girard N, Spicer J, Provencio M, Lu S, Wang C, Awad M, et al. Neoadjuvant nivolumab (N) + platinum-doublet chemotherapy (C) for resectable NSCLC: 3-y update from CheckMate 816. ELCC 2023; abstract 84O.